 | Up a level |
Journal Article
Ansen, S., Schultheis, A., Hellmich, M., Leenders, F., Zander, T., Michels, S., Brockmann, M., Stoelben, E., Groen, H., Timens, W., Buettner, R., Thomas, R. K., Perner, S. and Wolf, J. (2014). PD-L1 expression and genotype in Non-Small Cell Lung Cancer (NSCLC). Oncol. Res. Treat., 37. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262
Heuckmann, J. M. and Thomas, R. K. (2015). A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Ann. Oncol., 26 (9). S. 1830 - 1838. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nogova, L., Malchers, F., Bitter, E., Michels, S., Fischer, R., Scheffler, M., Gardizi, M., Brandes, V., Scheel, A. H., Kambartel, K., Krueger, S. 
ORCID: 0000-0002-1658-5993, Serke, M., Isaacs, R., Porter, D., Buettner, R., Thomas, R. K. and Wolf, J.
(2017).
Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center.
Oncol. Res. Treat., 40.
S. 137 - 139.
BASEL:
KARGER.
ISSN 2296-5262
Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R. and Wolf, J. (2020). FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Oncol. Res. Treat., 43 (SUPPL 4). S. 146 - 148. BASEL: KARGER. ISSN 2296-5262
Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Hero, B., Schramm, A., Schulte, J. H., Herrmann, C., O'Sullivan, R. J., Westermann, F., Thomas, R. K. and Fischer, M. (2016). Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Oncol. Res. Treat., 39. S. 43 - 44. BASEL: KARGER. ISSN 2296-5262
Peifer, M., Roels, F., Hertwig, F., Menon, R., Kraemer, A., Buettner, R., Perner, S., Schramm, A., Schulte, J. H., Hero, B., O'Sullivan, R. J., Westermann, F., Thomas, R. K. and Fischer, M. (2015). TELOMERASE ACTIVATION BY RECURRENT GENOMIC REARRANGEMENTS IN HIGH-RISK NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S149 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017
Sos, M. L. and Thomas, R. K. (2012). Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene, 31 (46). S. 4811 - 4815. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5594
Volz, C., Zaplatina, A., Siobal, M., Chatterjee, S., Schoettle, J., Meder, L., Florin, A., Koker, M., Buettner, R., Miao, H., Wang, B., Hallek, M., Acker-Palmer, A. S., Heukamp, L. C., Thomas, R. K. and Ullrich, R. (2016). Anti angiogenic treatment induces tumor cell invasion and metastasis via EphA2 signaling in NSCLC. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262